Top 10 Companies in the 1,1‑Carbonyl‑bis‑imidazole (CAS 530‑62‑1) Market (2026): Market Leaders Driving Advanced Chemical Synthesis

MARKET INSIGHTS

Global 1,1‑Carbonyl‑bis‑imidazole (CAS 530‑62‑1) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

1,1‑Carbonyl‑bis‑imidazole (CDI), identified under CAS number 530‑62‑1, is a highly versatile and reactive coupling reagent widely employed in organic synthesis. It serves as a carbonylating agent that facilitates the formation of amide, ester, and carbamate bonds under mild reaction conditions without generating hazardous by‑products, making it a preferred choice in pharmaceutical synthesis, peptide chemistry, and specialty chemical manufacturing.

The market is gaining steady momentum, driven primarily by increasing demand from the pharmaceutical industry for high‑purity coupling reagents in active pharmaceutical ingredient (API) synthesis. Furthermore, the growing adoption of CDI in agrochemical formulations and advanced polymer research is broadening its application scope. Key manufacturers such as Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Alfa Aesar continue to expand their product offerings to meet the rising global demand.

1,1‑Carbonyl‑bis‑imidazole (CAS 530‑62‑1) Market – View in Detailed Research Report

🔟 1. TCI Chemicals (Tokyo Chemical Industry Co., Ltd.)

Headquarters: Tokyo, Japan
Key Offering: Pharmaceutical‑grade CDI, specialty reagents for fine chemistry

TCI Chemicals has established a robust global distribution network that ensures consistent supply of high‑purity CDI to pharmaceutical and research clients. Its production facility incorporates advanced moisture‑control systems that preserve reagent integrity, addressing the inherent hygroscopic nature of CDI.

Sustainability Initiatives:

• Implementation of closed‑loop solvent recycling in CDI synthesis
• Investment in renewable energy for manufacturing sites
• Compliance with ISO 14001 environmental management standards

9️⃣ 2. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany & Kenilworth, USA
Key Offering: GMP‑grade CDI, comprehensive reagent portfolio

Sigma‑Aldrich’s dual role as a manufacturer and distributor provides end users with streamlined procurement and technical support. The company’s stringent quality control processes, including HPLC purity verification and residual solvent analysis, reinforce its reputation for reliability in regulated environments.

Sustainability Initiatives:

• Reduction of hazardous waste through process optimization
• Targeted carbon‑neutrality program for 2030
• Partnerships with academic institutions on green chemistry projects

8️⃣ 3. Alfa Aesar (Thermo Fisher Scientific)

Headquarters: Wilmington, USA
Key Offering: Technical‑grade CDI, bulk packaging options

Alfa Aesar’s extensive product catalog caters to both research and industrial segments. The company’s focus on scalable production and cost‑effective pricing makes it a popular choice for large‑scale synthesis where high volumes are required.

Sustainability Initiatives:

• Energy‑efficient manufacturing lines with real‑time monitoring
• Water‑reduction initiatives across production facilities
• Transparent supply‑chain traceability reporting

7️⃣ 4. Fluorochem Ltd.

Headquarters: London, United Kingdom
Key Offering: Specialty CDI for polymer chemistry, advanced functionalisation reagents

Fluorochem’s expertise in fluorinated chemistry extends to CDI production, where precise control over reaction conditions is essential. The firm supports polymer researchers with tailored reagent specifications that enable fine‑tuned surface modifications.

Sustainability Initiatives:

• Use of greener solvents in CDI synthesis
• Participation in the UK’s Green Chemistry Initiative
• Investment in waste‑reduction technologies for by‑product recovery

6️⃣ 5. Carbosynth Ltd.

Headquarters: Manchester, United Kingdom
Key Offering: Bio‑active CDI, custom synthesis services

Carbosynth’s focus on bioconjugation and medicinal chemistry positions it as a key supplier for researchers developing antibody‑drug conjugates and other biologics. The company offers bespoke synthesis routes that integrate CDI chemistry seamlessly into complex workflows.

Sustainability Initiatives:

• Adoption of catalytic CDI alternatives to reduce stoichiometric waste
• Collaboration with universities on green chemistry curricula
• Implementation of ISO 9001 quality management systems

5️⃣ 6. Oakwood Chemical

Headquarters: Lexington, USA
Key Offering: Research‑grade CDI, rapid‑turnaround service

Oakwood Chemical’s agility in production and logistics enables it to meet the tight timelines of early‑stage discovery programs. Its strong technical support network assists clients in troubleshooting CDI‑mediated reactions.

Sustainability Initiatives:

• Use of recyclable packaging materials for laboratory shipments
• Development of solvent‑free CDI synthesis routes
• Carbon‑offset contributions for shipping operations

4️⃣ 7. Combi‑Blocks, Inc.

Headquarters: West Lafayette, USA
Key Offering: Building blocks incorporating CDI, peptide‑coupling reagents

Combi‑Blocks supplies a range of pre‑functionalised building blocks that streamline peptide synthesis. The inclusion of CDI chemistry in its catalog allows chemists to perform multi‑step couplings with minimal purification steps.

Sustainability Initiatives:

• Implementation of green solvent protocols in building block synthesis
• Recycling of CDI by‑products where feasible
• Compliance with REACH and TSCA regulations across all products

3️⃣ 8. Hangzhou Hairui Chemical Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: Cost‑effective CDI, bulk supply for CDMO clients

Hangzhou Hairui’s production capacity supports the growing domestic demand for CDI in China’s expanding CDMO sector. The company focuses on maintaining quality while scaling volumes to meet large‑batch synthesis needs.

Sustainability Initiatives:

• Adoption of energy‑efficient reactors in CDI production
• Waste‑water treatment upgrades to meet local environmental standards
• Participation in China’s National Green Chemistry Programme

2️⃣ 9. Shanghai Aladdin Biochemical Technology Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Advanced CDI for bioconjugation, specialty reagents

Shanghai Aladdin’s portfolio includes CDI formulations tailored for high‑throughput bioconjugation assays. Its rapid‑delivery service supports time‑critical research projects.

Sustainability Initiatives:

• Implementation of green‑chemistry guidelines in reagent development
• Investment in renewable energy for manufacturing sites
• Transparent reporting of environmental metrics

1️⃣ 10. BASF SE

Headquarters: Ludwigshafen, Germany
Key Offering: Fine‑chemical CDI, integrated supply for large‑scale production

BASF’s extensive fine‑chemical division supplies high‑purity CDI to pharmaceutical and specialty chemical manufacturers. The company leverages its global logistics network to provide consistent delivery schedules and robust quality assurance.

Sustainability Initiatives:

• Carbon‑neutral manufacturing targets for 2030
• Continuous improvement of process yield and waste reduction
• Integration of life‑cycle assessment in product development

1,1‑Carbonyl‑bis‑imidazole (CAS 530‑62‑1) Market – View in Detailed Research Report

1,1‑Carbonyl‑bis‑imidazole (CAS 530‑62‑1) Market – View in Detailed Research Report

Outlook: The Future of 1,1‑Carbonyl‑bis‑imidazole (CAS 530‑62‑1) Market

Over the next decade, the CDI market will continue to expand as the pharmaceutical sector pushes for more efficient and cleaner synthesis routes. The shift toward green chemistry, coupled with the rising importance of peptide‑based therapeutics, will sustain demand for high‑purity CDI. Regional manufacturing hubs in Asia‑Pacific are expected to capture a larger share of the market, driven by cost advantages and growing CDMO infrastructure.

Future Trends Shaping the Market

• Integration of CDI into continuous manufacturing platforms, reducing batch‑to‑batch variability.
• Development of alternative, lower‑toxicity coupling reagents that mimic CDI’s reactivity profile.
• Enhanced moisture‑resistant packaging solutions, expanding CDI’s applicability in resource‑constrained environments.
• Increased collaboration between reagent suppliers and CDMOs to co‑develop customized CDI formulations for specific therapeutic classes.